Terence Rooney

5.1k citations

53 papers · 3.9k indexed · 4 hit papers · h-index 28

Impact in

Rheumatology top 0.1%
- Rheumatoid Arthritis Research and Therapies
- Systemic Lupus Erythematosus Research
- Spondyloarthritis Studies and Treatments
Hematology top 0.5%
- Autoimmune and Inflammatory Disorders Research

Papers in

Rheumatology 47
- Rheumatoid Arthritis Research and Therapies 47
- Systemic Lupus Erythematosus Research 16
- Spondyloarthritis Studies and Treatments 5
Hematology 26
- Autoimmune and Inflammatory Disorders Research 26

Co-authors: Douglas Schlichting William L. Macias Scott D. Beattie Stephanie de Bono Peter C. Taylor Mark C. Genovese C. Gaich Désirée van der Heijde
Journals: Annals of the Rheumatic Diseases (19 papers)The Journal of Rheumatology (5 papers)Modern Rheumatology (3 papers)Arthritis Research & Therapy (3 papers)Arthritis & Rheumatology (3 papers)
Partner nations: United States Japan United Kingdom

In The Last Decade

Terence Rooney

51 papers receiving 3.8k citations

Hit Papers

align trajectories log scale

Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis 2017 · 621 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2017 New England Journal of Medicine
2016 Arthritis & Rheumatology
2016 Annals of the Rheumatic Diseases
2016 New England Journal of Medicine

Peers

Countries citing papers authored by Terence Rooney

Since Specialization

Citations

This map shows the geographic impact of Terence Rooney's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Terence Rooney with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Terence Rooney more than expected).

Fields of papers citing papers by Terence Rooney

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Terence Rooney. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Terence Rooney. The network helps show where Terence Rooney may publish in the future.

Co-authors

The 25 scholars most cited alongside Terence Rooney, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Terence Rooney Line = papers co-authored together Terence Rooney links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis The Lancet Rheumatology ·Mark C. Genovese, Josef S Smolen, Tsutomu Takeuchi, Gerd R Burmester, Dennis Brinker, Terence Rooney, Jinglin Zhong, Daojun Mo, Chadi Saifan, Anabela Cardoso, Maher Issa, Wen‐Shuo Wu, Kevin Winthrop	2020	55
2	Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis Annals of the Rheumatic Diseases ·Yoshiya Tanaka, Bruno Fautrel, Edward Keystone, Robert Ortmann, Li Xie, Baojin Zhu, Maher Issa, Himanshu J. Patel, C. Gaich, Stephanie de Bono, Terence Rooney, Peter C. Taylor	2019	23
3	Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs RMD Open ·Désirée van der Heijde, Maxime Dougados, Ying‐Chou Chen, Maria Greenwald, Edit Drescher, Rena Klar, Li Xie, Inmaculada de la Torre, Terence Rooney, Sarah L Witt, Douglas Schlichting, Stephanie de Bono, Paul Emery	2018	17
4	Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies Annals of the Rheumatic Diseases ·Peter C. Taylor, Joel M. Kremer, Paul Emery, Steven H. Zuckerman, Giacomo Ruotolo, Jinglin Zhong, Lei Chen, Sarah Witt, Chadi Saifan, Monika Kurzawa, James D. Otvos, Margery A. Connelly, William L. Macias, Douglas Schlichting, Terence Rooney, Stephanie de Bono, Iain B. McInnes	2018	47
5	Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study Annals of the Rheumatic Diseases ·Tsutomu Takeuchi, Mark C. Genovese, Boulos Haraoui, Zhanguo Li, Li Xie, Rena Klar, Ana L Pinto-Correia, S. Otawa, Pedro López‐Romero, Inmaculada de la Torre, William L. Macias, Terence Rooney, Josef S Smolen	2018	60
6	BARICITINIB INHIBITS RADIOGRAPHIC PROGRESSION OF STRUCTURAL JOINT DAMAGE AT 1 YEAR IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) AND AN INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (CSDMARDS) Internal Medicine Journal ·Mark C. Genovese, Désirée van der Heijde, Maxime Dougados, Y. Chen, Maria Greenwald, Edit Drescher, Rena Klar, Xie Li-hu, Inmaculada de la Torre, Terence Rooney, Sarah Witt, D. Schlichting, Stephanie de Bono, Paul Emery	2017	1
7	Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis New England Journal of Medicine ·Peter C. Taylor, Edward Keystone, Désirée van der Heijde, Michael E. Weinblatt, Liliana Morales, Jaime Reyes Gonzaga, S. S. Yаkushin, Taeko Ishii, Kahaku Emoto, Scott D. Beattie, Vineet M. Arora, C. Gaich, Terence Rooney, Douglas Schlichting, William L. Macias, Stephanie de Bono, Yoshiya Tanaka Hit paper breakdown →	2017	621
8	Psychometric properties of morning joint stiffness duration and severity measures in patients with moderately to severely active rheumatoid arthritis Health and Quality of Life Outcomes ·Elizabeth D. Bacci, Amy M. DeLozier, Chen‐Yen Lin, C. Gaich, Terence Rooney, Richard Hoffman, Kathleen W. Wyrwich	2017	11
9	Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study Annals of the Rheumatic Diseases ·Edward Keystone, Peter C. Taylor, Yoshiya Tanaka, C. Gaich, Amy M. DeLozier, Anna Dudek, Jorge Velasco Zamora, Jose Arturo Covarrubias Cobos, Terence Rooney, Stephanie de Bono, Vineet M. Arora, Bruno Linetzky, Michael E. Weinblatt	2017	83
10	Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study Annals of the Rheumatic Diseases ·Maxime Dougados, Désirée van der Heijde, Ying‐Chou Chen, Maria Greenwald, Edit Drescher, Jiajun Liu, Scott D. Beattie, Sarah Witt, Inmaculada de la Torre, C. Gaich, Terence Rooney, Douglas Schlichting, Stephanie de Bono, Paul Emery Hit paper breakdown →	2016	301
11	Baricitinib, an Oral Janus Kinase (JAK) 1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to cDMARD Therapy: Results of the Phase 3 RA-BUILD Study The Journal of Rheumatology ·Maxime Dougados, D. van der Heijde, Y.C. Chen, Maria Greenwald, Edit Drescher, J.J. Liu, Scott D. Beattie, Inmaculada de la Torre, Terence Rooney, D. Schlichting, Stephanie de Bono, P. Emery, Arthur Bookman	2016	2
12	Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study The Journal of Rheumatology ·Yoshiya Tanaka, Kahaku Emoto, Zhihong Cai, Takehiro Aoki, Douglas Schlichting, Terence Rooney, William L. Macias	2016	105
13	Baricitinib in Patients with Refractory Rheumatoid Arthritis New England Journal of Medicine ·Mark C. Genovese, Joel Kremer, Omid Zamani, Charles Ludivico, Marek Krogulec, Li Xie, Scott D. Beattie, Alisa E. Koch, Tracy Cardillo, Terence Rooney, William L. Macias, Stephanie de Bono, Douglas Schlichting, Josef S Smolen Hit paper breakdown →	2016	458
14	Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON) Annals of the Rheumatic Diseases ·Josef S Smolen, Joel M. Kremer, C. Gaich, Amy M. DeLozier, Douglas Schlichting, Li Xie, Ivaylo Stoykov, Terence Rooney, Paul Bird, Juan Miguel Sánchez Bursón, Mark C. Genovese, Bernard Combe	2016	84
15	Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate Annals of the Rheumatic Diseases ·Edward Keystone, Peter C. Taylor, Edit Drescher, Douglas Schlichting, Scott D. Beattie, Pierre‐Yves Berclaz, Chin H. Lee, Rosanne Fidelus-Gort, Monica Luchi, Terence Rooney, William L. Macias, Mark C. Genovese	2014	225
16	Levels of plasma fibrinogen are elevated in well-controlled rheumatoid arthritis Lara D. Veeken ·Terence Rooney, Rebecca Scherzer, Judy K. Shigenaga, John Graf, John B. Imboden, Carl Grünfeld	2011	36
17	Synovial tissue and serum biomarkers of disease activity, therapeutic response and radiographic progression: analysis of a proof-of-concept randomised clinical trial of cytokine blockade Annals of the Rheumatic Diseases ·Terence Rooney, P Roux‐Lombard, Douglas J. Veale, Oliver FitzGerald, Jean‐Michel Dayer, Barry Bresnihan	2009	33
18	Synovial macrophages as a biomarker of response to therapeutic intervention in rheumatoid arthritis: standardization and consistency across centers. PubMed ·Barry Bresnihan, Daniëlle M. Gerlag, Terence Rooney, Tom Smeets, Carla A. Wijbrandts, David Boyle, Oliver FitzGerald, Bruce Kirkham, Iain B. McInnes, Malcolm Smith, Ann-Kristin Ulfgren, Douglas J. Veale, Paul P Tak	2007	58
19	Microscopic measurement of inflammation in synovial tissue: inter-observer agreement for manual quantitative, semiquantitative and computerised digital image analysis Annals of the Rheumatic Diseases ·Terence Rooney, Barry Bresnihan, Jan Andersson, Martina Gogarty, MC Kraan, Harold R. Schumacher, A.‐K. Ulfgren, Douglas J. Veale, Peter Youssef, Paul P. Tak	2007	19
20	Synovial tissue interleukin-18 expression and the response to treatment in patients with inflammatory arthritis Annals of the Rheumatic Diseases ·Terence Rooney, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	2004	67

About Terence Rooney

Terence Rooney is a scholar working on Rheumatology, Hematology, Genetics, Pathology and Forensic Medicine and Immunology, having authored 53 papers that have together received 3.9k indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (47 papers), Autoimmune and Inflammatory Disorders Research (26 papers), Chronic Lymphocytic Leukemia Research (21 papers), Systemic Lupus Erythematosus Research (16 papers), Cytokine Signaling Pathways and Interactions (8 papers), Lymphoma Diagnosis and Treatment (5 papers), Immunodeficiency and Autoimmune Disorders (5 papers) and Spondyloarthritis Studies and Treatments (5 papers). The work is most often cited by research in Rheumatology (2.9k citations), Hematology (1.4k citations), Genetics (857 citations), Immunology (806 citations) and Oncology (932 citations). Terence Rooney has collaborated with scholars based in United States, Japan and United Kingdom. Frequent co-authors include Douglas Schlichting, William L. Macias, Scott D. Beattie, Stephanie de Bono, Peter C. Taylor, Mark C. Genovese, C. Gaich, Désirée van der Heijde, Yoshiya Tanaka and Tsutomu Takeuchi. Their work appears in journals such as Annals of the Rheumatic Diseases, The Journal of Rheumatology, Modern Rheumatology, Arthritis Research & Therapy and Arthritis & Rheumatology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact